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ARTICLE OPEN
Early constipation predicts faster dementia onset
in Parkinson’s disease
M. Camacho 1✉, A. D. Macleod 2, J. Maple-Grødem 3,4, J. R. Evans5, D. P. Breen6,7,8, G. Cummins1, R. S. Wijeyekoon1,
J. C. Greenland1, G. Alves 3,4, O. B. Tysnes9, R. A. Lawson10, R. A. Barker 1,11 and C. H. Williams-Gray1
Constipation is a common but not a universal feature in early PD, suggesting that gut involvement is heterogeneous and may be
part of a distinct PD subtype with prognostic implications. We analysed data from the Parkinson’s Incidence Cohorts Collaboration,
composed of incident community-based cohorts of PD patients assessed longitudinally over 8 years. Constipation was assessed
with the MDS-UPDRS constipation item or a comparable categorical scale. Primary PD outcomes of interest were dementia, postural
instability and death. PD patients were stratified according to constipation severity at diagnosis: none (n= 313, 67.3%), minor (n=
97, 20.9%) and major (n= 55, 11.8%). Clinical progression to all three outcomes was more rapid in those with more severe
constipation at baseline (Kaplan–Meier survival analysis). Cox regression analysis, adjusting for relevant confounders, confirmed a
significant relationship between constipation severity and progression to dementia, but not postural instability or death. Early
constipation may predict an accelerated progression of neurodegenerative pathology.
npj Parkinson’s Disease            (2021) 7:45 ; https://doi.org/10.1038/s41531-021-00191-w
INTRODUCTION
Although Parkinson’s disease (PD) is characterized as a move-
ment disorder, it is associated with significant non-motor
features including gastrointestinal (GI) dysfunction1,2 such as
constipation, dysphagia, sialorrhea, delayed gastric emptying
and reflux3,4. Constipation is one of the most common non-
motor PD symptoms5 and can significantly impact on the
patient’s quality of life6. Individuals with constipation are at
greater risk of developing PD7 and it is now a recognized feature
of prodromal PD8,9.
Research efforts on the gut–brain axis have increased dramati-
cally and there is accumulating evidence for a possible role of gut
dysfunction in the early pathogenesis of PD10–12; however, its link to
disease progression has received less attention13,14. James Parkin-
son, in An Essay on the Shaking Palsy15, reported the amelioration of
PD symptoms in two cases following the alleviation of constipation
after laxative prescription, which made him question the role of the
GI tract in the disease process. More recent studies16,17 reporting
motor improvement following constipation treatment suggest that,
more than 200 years later, the question remains of interest but
more basic and clinical research evidence is needed to confirm this
association.
It has been proposed that changes in gut function may impact
on PD through alteration in the gut microbiota composition11.
Clinical trials with probiotics (Clinicaltrials.gov identifier
NCT04140760) and faecal microbiota transplantation (Clinical-
trials.gov identifier NCT03808389) are being explored as novel
therapeutic approaches18. The mechanistic basis of this is unclear,
but one hypothesis is that early alpha-synuclein pathology in the
enteric nervous system in PD leads to reduced gut motility, which
results in changes in the microbiome. Both local alpha-synuclein
deposition and an altered microbiome may contribute to low-
grade gut and systemic inflammation, in turn exacerbating brain
inflammation and neurodegeneration and leading to more rapid
disease progression19,20. While it could be argued that early
pathological changes in the enteric nervous system in PD and
associated constipation simply reflect a more malignant dissemi-
nated disease process, this seems unlikely given that constipation
can predate the onset of motor symptoms in PD by 10–16 years21.
To date, although there are effective therapies for some of the
key motor features of PD, there are still no disease-modifying
treatments. At the 10 year longitudinal assessment of an incident
population-representative PD cohort (CamPaIGN), only 23% of
patients had a good outcome (surviving free of dementia/postural
instability), while 68% of patients had developed postural
instability and 46% had developed dementia22. Constipation is a
relatively preventable and treatable aspect of PD, and if found to
be causally linked to long-term PD prognosis, warrants further
consideration as a target for disease modification.
RESULTS
Three participants with missing constipation items and two
patients with Mini Mental State Examination (MMSE) scores highly
suggestive of dementia (MMSE < 18) at the baseline visit were
excluded. For survival analysis of postural instability, patients with
H&Y3+ at baseline were excluded (n= 44). The total sample size
was 465 patients for the dementia and mortality analyses and 421
patients for the postural instability analysis. Participants were
longitudinally assessed for up to 8.6 years from diagnosis, with an
average follow-up time of 5.1 years (SD= 2.5) from diagnosis.
At baseline, 20.9% of patients had ‘minor’ constipation (n= 97)
and 11.8% of patients had ‘major’ constipation (n= 55), while 67.3%
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of patients (n= 313) did not report any constipation (Table 1).
Patients with ‘major’ constipation had higher baseline Movement
Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-
UPDRS-III) scores compared to the ‘minor’ and no constipation
groups (p < 0.01). Hoehn and Yahr (H&Y) stage and age were also
higher in patients with ‘major’ constipation compared to the no
constipation group. Constipated and non-constipated patients did
not differ in terms of sex, smoking status, disease duration, time
between symptom onset and diagnosis, levodopa equivalent daily
dose (LEDD), years of education, MMSE, number of comorbidities at
baseline, presence of vascular disease or diabetes, or use of
anticholinergic or opiate drugs at baseline.
Dementia
Kaplan–Meier survival analysis indicated faster progression to
dementia in more constipated patients (Fig. 1a). At the study
endpoint, the cumulative proportion with dementia was 20.9% of
patients in the no constipation group versus 38.3% in the ‘minor’
constipation and 47.0% in the ‘major’ constipation group. The no
constipation group had the longest mean time to dementia of 7.5
years (95% CI, 7.3–7.8), followed by the ‘minor’ constipation group
at 7.1 years (95% CI, 6.6–7.5) and the ‘major’ constipation group
with the shortest time of 6.0 years (95% CI, 5.2–6.8). A log-rank test
confirmed that survival distributions for the three groups were
significantly different (χ2(2)= 15.364, p < 0.0001). Pairwise log-rank
comparisons indicated that this difference was most pronounced
for the no constipation versus ‘major’ group (‘major’ versus no
constipation χ2(1)= 13.707, p < 0.0001; ‘minor’ versus no constipa-
tion χ2(1)= 3.888, p= 0.049; ‘minor’ versus ‘major’ constipation
χ2(1)= 3.755, p= 0.053). Cox regression analysis confirmed that
constipation severity was a significant predictor of dementia
outcome, after adjusting for covariates (Table 2; HR= 1.45, p=
0.008). Similar significant results were obtained if H&Y stage was
included as a covariate instead of MDS-UPDRS-III motor score in
the Cox regression model (HR(constipation)= 1.35, p= 0.038). To
investigate the possibility of selective attrition in the different
constipation severity groups, we compared baseline cognitive and
baseline motor severity scores between patients who were lost to
follow-up without a known dementia outcome (36%) and the
group who either reached dementia or remained active at the
study’s endpoint (64%). There were no between-group differences
in terms of baseline MDS-UPDRS-III and MMSE scores in the
‘minor’ versus ‘major’ constipation groups (data not shown).
However in the no constipation group, we observed a marginal
difference in baseline MMSE (mean of active group= 28.5, mean
of lost to follow-up group= 28.2; U= 12,717.5, Z= 2.050, p=
0.040) and a more significant difference in baseline MDS-UPDRS-III,
which was higher in those who were lost to follow-up without a
known outcome (mean of active group= 26.9, mean of lost to
follow-up group= 33.8; U= 7689.0, Z=−4.539, p < 0.0001). This
suggests selective drop-out of patients with more severe motor
impairment at baseline in the no constipation group, which could
have a confounding effect on our results, but this would not have
impacted on the observed difference we found between the
‘minor’ and ‘major’ constipation groups.
Postural instability
Baseline constipation severity was associated with faster progres-
sion to development of postural instability as defined by H&Y3 or
higher (Fig. 1b). At the study endpoint, the cumulative percentage
of patients with an H&Y score ≥3 was 35.4% in the no constipation
group versus 52.3% in the ‘minor’ constipation and 59.8% in the
‘major’ constipation group. The no constipation group had the
longest mean time to H&Y3+ of 6.9 years (95% CI, 6.6–7.3)
compared to 6.4 years (95% CI, 5.9–7.0) in the ‘minor’ constipation
group and 5.5. years (95% CI, 4.7–6.3) in the ‘major’ constipation
group. H&Y3+ survival distributions for the three constipation
severity groups were significantly different (χ2(2)= 9.882, p=
0.007). Pairwise log-rank comparisons indicated that this was
mainly driven by the difference between the ‘major’ versus the no
constipation group (‘major’ versus no constipation χ2(1)= 7.294,
p= 0.007; ‘minor’ versus no constipation χ2(1)= 4.314, p= 0.038;
‘minor’ versus ‘major’ constipation χ2(1)= 1.310, p= 0.252).
However, Cox regression analysis did not confirm a statistically
significant association between constipation severity and time to
postural instability when adjusting for age, sex, baseline MDS-
UPDRS-III and cohort study (Table 2).
Death
The association between constipation and time to death was also
investigated (Fig. 1c). At the study endpoint, the cumulative
mortality proportions were 44.1% in the no constipation group,
49.1% in the ‘minor’ constipation and 64.7% in the ‘major’
constipation group.
Table 1. Baseline demographic and clinical characteristics of PD













62.0% 61.9% 54.3% 0.469
Smoking status
(% smokers)
5.1% 7.2% 3.6% 0.07












































































Vascular disease 42.8% 44.3% 56.4% 0.175
Diabetes 8.6% 7.2% 7.3% 0.877
Anticholinergic
medication
2.9% 1.0% 1.8% 0.560
Opiate
medication
3.5% 1.0% 3.6% 0.436
Values shown are mean ± standard deviation and (range). Continuous
variables were compared using Kruskal–Wallis test and categorical
variables compared using Chi square tests. Significance threshold is p <
0.05. Overall statistical differences are represented by * and pairwise
comparisons between groups are represented by ♯p < 0.05, ₫p < 0.005 and
∞p < 0.001. H&Y Hoehn and Yahr, MDS-UPDRS-III Movement Disorders
Society-Unified Parkinson’s Disease Rating Scale, L-Dopa Levodopa, MMSE
Mini Mental State Examination.
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Mean time to death was 10.0 years (95% CI, 9.7–10.4) in the no
constipation group, and 9.7 years (95% CI, 9.0–10.5) in the
‘minor’ constipation group, while the ‘major’ constipation group
had the shortest mean time to death of 8.7 years (95% CI,
7.8–9.6). The survival distributions for the three constipation
severity groups were significantly different (χ2(2)= 6.286, p=
0.046), which was driven by the difference between the ‘major’
versus the no constipation group (χ2(1)= 6.105, p= 0.013), with
no differences between the ‘minor’ versus no constipation group
and between the ‘minor’ and ‘major’ groups (χ2(1)= 0.537, p=
0.463; χ2(1)=1.922, p= 0.166, respectively). This association did
not withstand Cox regression analysis after correction for the
potentially confounding effects of age, sex, MDS-UPDRS-III,
MMSE and study centre (Table 2).
Alternate measures of autonomic and GI dysfunction
Because early autonomic dysfunction has been associated with
more rapid disease progression and shorter survival in patients
with PD23, we investigated whether constipation was a proxy
measure of autonomic dysfunction in our sample. We first
conducted a chi square test of independence between constipa-
tion severity and postural hypotension. Because 22.2% of
expected cell frequencies were lower than five in both tests,
we dichotomized the variables and repeated the analysis.
Postural hypotension was not significantly higher (p= 0.243) in
the constipated group (23.1%) compared with the non-
constipated group (17.0%). Cox regression models for groups
stratified by postural hypotension (PICNICS cohort, n= 278) did
not show any association with time to dementia (HR= 0.58, p=
0.238), postural instability (HR= 1.30, p= 0.305) or death (HR=
0.92, p= 0.674). We also analysed dysphagia as an alternative
symptom of GI dysfunction associated with more advanced
disease. Dysphagia was significantly higher (p= 0.031) in the
constipated group (22.4%) compared with the non-constipated
group (14.4%). However, Cox regressions indicated no relation-
ship between dysphagia and time to dementia (HR= 1.03, p=
0.884), time to postural instability (HR= 1.01, p= 0.942) or death
(HR= 1.17, p= 0.353).
DISCUSSION
We investigated the relationship between early constipation and
subsequent disease progression in a representative population of
incident, community-based PD cases and demonstrated that
constipation severity at disease onset predicts faster progression
to dementia. Our data also suggest a similar trend for an
association with faster motor progression to H&Y stage 3 and
death, although these associations did not reach statistical
significance in Cox regression modelling with correction for
covariates. Our findings support previous research on the
association of constipation with disease duration/severity24,25,
but our study investigates the predictive relationship of constipa-
tion severity at the time of diagnosis with the key disease
milestones of dementia, postural instability and death. To date,
only one other study by Jones et al.14 has analysed the
longitudinal relationship between severity of GI symptoms and
cognitive impairment in newly diagnosed PD patients. Jones et al.
used a composite GI symptom score rather than constipation
per se and explored the relationship between longitudinal GI
scores and cognitive performance over time, rather than assessing
whether baseline GI symptoms predict subsequent cognitive
outcome. Our results are in line with their study which reported
that a higher frequency of GI symptoms was associated with
worse cognitive performance over 5 years as well as mild
cognitive impairment and PD dementia (PDD). Similar to our
results, their findings suggested that cognitive function was not
significantly related to non-GI autonomic symptoms, indicating
that these observations are specific to the GI system rather than to
autonomic dysfunction per se.
The pathophysiological basis of this association between early
gut dysfunction and PD progression is unknown but accumulation
of alpha-synuclein protein aggregates in the gut in early stages of
PD has led to the hypothesis that, in a subset of patients, PD
pathology may begin in the gut before spreading to connected
areas of the nervous system26–28. Colonic alpha-synuclein is
associated with chronic constipation and pathophysiological
changes in the intestinal wall20,29. Patients with early PD have
been shown to have increased intestinal permeability, altered
microbiota composition, increased bacterial translocation through
the gut wall, and higher levels of inflammatory cytokines in the GI
tract20. The presence of lipopolysaccharides (LPS) and related
bacterial proteins has been shown to be increased in brains of
patients with Alzheimer’s Disease, indicating that endotoxins can
access the brain30. Furthermore, peripheral administration of LPS
in humans can cause rapid microglial activation and increase in
peripheral inflammatory cytokines31. So, it is possible that gut
changes in PD may trigger a systemic chronic immune response
which, in turn, promotes faster progression12,32,33. While the
association between the microbiome and dementia risk in PD has
not yet been investigated in long-term studies, cognitive
dysfunction (particularly impaired attention, mental flexibility
and executive function) has been reported to be associated with
gut microbiota composition in cross-sectional and longitudinal
studies in non-PD cohorts (mainly composed of obese indivi-
duals)34–37. In a population-based cohort study of patients with
inflammatory bowel disease, patients had a higher risk of
subsequent development of dementia, and with a younger
average age of onset than the general population38. In PD,
Wijeyekoon et al.39 have found elevated bacterial endotoxin levels
in the serum of PD patients compared to controls, particularly in
those patients at higher risk of an early dementia. Hence early
constipation and associated translocation of bacterial products
into the circulation may have particular relevance for cognitive
decline in PD.
An alternative explanation for our observation is that the early
constipation associated with a more rapid development to a
















































































Fig. 1 Survival analysis for major outcomes of Parkinson’s disease according to constipation severity. Kaplan–Meier survival analysis for
dementia (a), postural instability (b) and mortality (c) in groups stratified by constipation severity. (*, **, **** denote p ≤ 0.05, p ≤ 0.01, p ≤
0.0001, respectively, log-rank test).
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dementia reflects a more malignant disseminated form of PD,
with widespread evolving alpha-synuclein pathology from
disease onset. This fits with the observation that constipation
has been associated cross-sectionally with disease severity at
baseline40 but arguing against this interpretation is the fact that
in our study, constipation was associated with dementia
independently of disease motor severity at baseline. Of note,
while constipated patients had significantly higher rates of
dysphagia (an alternate measure of GID), at baseline, this was not
independently associated with time to dementia, postural
instability or death. Similarly, baseline postural hypotension (an
alternative measure of autonomic dysfunction) was not asso-
ciated with later disease outcomes. Importantly, our data
indicated no difference between constipation groups in terms
of disease duration, or motor symptom onset to diagnosis time,
suggesting that those with ‘major’ constipation were not
temporally more advanced in their disease course. Furthermore,
constipation commonly occurs as a prodromal symptom many
years before the onset of the typical motor and non-motor
features of PD21, which suggests it is not merely an indicator of
more advanced disease or dysautonomia.
Increasing evidence of distinct subtypes of PD with differential
progression trajectories holds important clinical implications41,42.
Fereshtehnejad et al.43 postulated that PD presenting features can
be clustered into three PD subtypes with different prognostic
trajectories, mainly motor/slow progression (cluster I), diffuse/
malignant (cluster II) and intermediate (cluster III). Despite
equivalent age and disease duration between groups, patients
in the malignant and intermediate clusters presented with high
constipation scores and other non-motor symptoms such as
orthostatic hypotension and REM sleep behaviour disorder (RBD),
unlike the slow progression subtype44. Furthermore, clusters II and
III were associated with faster cognitive decline. These results
support our finding that minor and major constipation problems
at diagnosis are associated with faster onset to PDD.
Major strengths of this study are the use of a large population-
representative cohort with incident, community-based PD and a
prospective follow-up period of up to 8 years after diagnosis. This
minimized selection bias and increased diagnostic certainty and
information on long-term prognosis. However, the study has
limitations. Despite the prolonged longitudinal follow-up, non-
survival distributions did not reach 50% of our sample and
extended follow-up would allow for an increased number of
events which will then permit calculations of median times to
outcome. Attrition is a common issue in longitudinal studies and
can introduce bias if there is selective drop out of cases at higher
risk of the outcome of interest. We did find that among cases with
no constipation, those who were lost to follow-up without a
dementia outcome had more motor impairment at baseline. It is
possible that this led to an underestimation of cumulative
dementia incidence in the no constipation group. GI comorbidities
and laxative use may have influenced constipation severity in
these cohorts, but detailed information on these factors was not
available. However, we investigated the potential confounding
effects of vascular disease, diabetes, anticholinergic and opiate
medication that have previously been associated with cognitive
decline or constipation severity and found no difference between
the constipation groups. We also did not have data on diet, which
may affect bowel function, the microbiome and risk of cognitive
impairment independently. However, irrespective of the aetiology
of constipation, and the effects of GI treatment on this, we
confirmed a link with faster subsequent disease progression,
which supports the hypothesis that measures to reduce constipa-
tion may be beneficial in terms of disease modification, assuming
these are causally linked.
Given the evidence that RBD is an important prodromal and
prognostic feature in PD and seems to be associated with
constipation42,45 it would have been interesting to have data on
RBD status. Unfortunately, polysomnography studies are difficult
to incorporate in large longitudinal studies and the REM Sleep
Behavior Disorder Screening Questionnaire (RBDSQ)46 was only
published after the start of these cohort studies; thus, these data
were not collected. A final limitation is the lack of a dedicated
constipation/GI questionnaire for stratification of the sample. We
used the constipation item of the MDS-UPDRS, which is commonly
used in PD research studies24. A number of different methods for
evaluating constipation have been used by previous authors, such
as the SCOPA-AUT14 or the NMSS47. To date, no PD-specific
psychometric instrument that reflects ROME-IV48 criteria is
available. Objective measures of gut transit time may be more
sensitive for detecting colonic dysfunction than symptom-based
questionnaires4, but are difficult to incorporate in large long-
itudinal studies. It is possible that our method of quantifying
constipation led to an underestimation of incidence and severity,
and further studies with more detailed constipation assessment
are needed to validate our findings.
In summary, our findings support the importance of studying
constipation in PD, showing that the presence and severity of this
symptom around the time of diagnosis is predictive of subsequent
progression to dementia. This supports the hypothesis that, in a
subset of patients, early constipation may be associated with an
accelerated progression of neurodegenerative pathology in the
brain, although the mechanism by which this occurs is currently
unknown.
Table 2. Cox regression models of the predictive role of constipation severity on time to postural instability, dementia and death, adjusting for
covariates.
Dementia
(χ2(6)= 71.912, p < 0.0001)
Postural instability
(χ2(5)= 100.414, p < 0.0001)
Death
(χ2(6)= 156.136, p < 0.0001)
Variable HR 95% CI P value HR 95% CI P value HR 95% CI P value
Constipation severity 1.45 1.10–1.91 0.008* 1.22 0.95–1.57 0.120 0.93 0.73–1.20 0.568
Age at diagnosis 1.06 1.03–1.09 <0.001* 1.09 1.07–1.12 <0.001* 1.11 1.08–1.14 <0.001*
Sex (female) 0.59 0.37–0.94 0.028* 1.02 0.71–1.47 0.913 0.51 0.35–0.35 0.001*
MDS-UPDRS-III 1.03 1.01–1.04 0.004* 1.03 1.02–1.05 <0.001* 1.04 1.02–1.05 <0.001*
MMSE 0.87 0.79–0.96 0.008* – – – 0.90 0.82–0.98 0.021*
Study centre 1.75 1.12–2.74 0.014* 0.64 0.45–0.91 0.013* 0.89 0.57–1.40 0.618
HR, hazard ratio, CI confidence interval, MDS-UPDRS-III Movement Disorders Society-Unified Parkinson’s Disease Rating Scale, MMSE Mini Mental State
Examination.
*Significance threshold p < 0.05.
M. Camacho et al.
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METHODS
We used data from the Parkinson’s Incidence Cohorts Collaboration (PICC),
a project that has pooled data from six prospective PD incidence cohorts in
Northern Europe (CamPaIGN, ICICLE-PD, NYPUM, ParkWest, PICNICS and
PINE)49. All patients were diagnosed with idiopathic PD using UK
Parkinson’s Disease Society Brain Bank criteria. Each study collected
demographic, clinical and genetic data close to the time of diagnosis and
at regular follow-up visits thereafter. Ethical approval for each study was
obtained from the relevant local ethics committees and all participants
gave written informed consent. Data on constipation at baseline were
available for two datasets: PICNICS (n= 280) and ParkWest (n= 190).
PICNICS follow-up assessments were performed every 18 months up to five
visits, and ParkWest follow-up assessments were performed every
12 months up to seven visits. Motor features were assessed using the
MDS-UPDRS-III in the PICNICS cohort and the UPDRS-III in the ParkWest
cohort (the latter was converted to MDS-UPDRS-III score using the formula
proposed by Goetz et al.)50. The MMSE was used in both cohorts to assess
global cognitive function. The number of comorbidities at baseline was
quantified in terms of the number of organ systems affected using the
Cumulative Illness Rating Scale (CIRS)51 for PICNICS and the Charlson
Comorbidity Index52 (CCI) for ParkWest. Presence of vascular disease and
diabetes at baseline was also specifically explored given that they have
been implicated in dementia risk. Vascular conditions included hyperten-
sion, angina, myocardial infarction, peripheral vascular disease, cerebro-
vascular disease (transient ischaemic attack, stroke) and atrial fibrillation/
cardiac arrhythmia. LEDD was calculated according to an adapted version
of the Tomlinson formula53 for both cohorts. Use of anticholinergic drugs
and opiate-based drugs was recorded at baseline. Constipation presence
and severity was assessed using item 1.11 of the MDS-UPDRS in the
PICNICS study and a comparable interview-based question for ParkWest
with a severity scale of 0–3. According to scores on this constipation item
at the participants’ baseline visit, the sample was stratified into three
groups: no constipation (score= 0), minor (score= 1) and major (score ≥ 2)
constipation. Dysphagia at baseline was considered as an alternative GI-
based predictor of outcome and was assessed using the MDS-UPDRS item
2.3 for PICNICS and a comparable question in ParkWest with a 0–3 severity
scale. Postural hypotension was considered as an alternative autonomic
predictor of outcome and was assessed using the MDS-UPDRS item 1.12
for the PICNICS cohort but was not assessed in ParkWest. Patients were
stratified as ‘none’, ‘minor’ and ‘major’ for dysphagia and postural
instability using the same methodology as for constipation.
Outcomes for this study were the development of PDD, postural
instability or death. Postural instability was defined as a consistent score of
3 or higher on the H&Y scale, with date of postural instability calculated as
the midpoint between the visit at which it was reached, and the preceding
visit. PDD onset was defined using the MDS PDD criteria54, with the date of
dementia determined similarly using the midpoint rule. Where patients
were lost to follow-up from the study, dementia diagnoses were
determined from clinical records or death certificates (n= 16/48 PICNICS;
n= 2/44 ParkWest), with date of dementia diagnosis being determined
using the midpoint between the date that dementia was first recorded and
the preceding clinical visit or research appointment, as appropriate.
Mortality status was obtained by continual follow-up, including review of
clinical notes and death certificates. Time to outcome (in years) was
computed by calculating the difference in days between outcome date
and PD diagnosis date and dividing by 365.
Statistical analysis
Data were analysed using IBM SPSS Statistics (Version 25). A significance
threshold of p < 0.05 was used. Graphs were generated using Graphpad
Prism version 8. Because Shapiro–Wilk’s test did not confirm distribution
normality for continuous variables we used the Kruskal–Wallis test for
between-group comparisons. Chi square tests of independence were used
for between-group comparisons for sex, smoking status, dysphagia,
postural hypotension, presence of vascular disease and diabetes, use of
opiate or anticholinergic medication.
Kaplan–Meier survival analyses of PD outcomes were performed in
groups stratified according to constipation severity, with date of diagnosis
as time= 0, and censoring at the last assessment for dementia and
postural instability analyses and at the study endpoint for the mortality
analysis. The proportional hazards assumption was checked by visual
inspection of Kaplan–Meier plots by level of covariates. Survival to the
events did not exceed 50% at the longest time point in the no constipation
and ‘minor’ constipation groups; thus, median times could not be
calculated and mean times are reported instead. Pairwise log-rank
comparisons were conducted to compare Kaplan–Meier curves between
groups. Cox regression analyses were performed to control for relevant
covariates (age, sex, study cohort, baseline motor severity (MDS-UPDRS-III)
and baseline global cognitive score (MMSE). Constipation was used as an
interval dependent variable. H&Y score was not included in the model
because of collinearity with MDS-UPDRS-III motor score. We tested an
interaction effect between study and constipation and it was non-
significant, thus not included in the regression models. For the dementia
analysis, education was also added to the regression model but was found
to be not significant and thus not included.
Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
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